{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:28:54Z","timestamp":1770438534570,"version":"3.49.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","progcardvascdis.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.pcad.2015.08.007","type":"journal-article","created":{"date-parts":[[2015,8,8]],"date-time":"2015-08-08T11:53:43Z","timestamp":1439034823000},"page":"247-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Ideal Anticoagulation Strategy in ST-Elevation Myocardial Infarction"],"prefix":"10.1016","volume":"58","author":[{"given":"Jaya","family":"Chandrasekhar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.pcad.2015.08.007_bb0005","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jcin.2013.03.013","article-title":"Relationship between myocardial reperfusion, infarct size, and mortality: the INFUSE-AMI (Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) trial","volume":"6","author":"Brener","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"issue":"23","key":"10.1016\/j.pcad.2015.08.007_bb0010","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/j.jacc.2009.08.024","article-title":"Impact of primary coronary angioplasty delay on myocardial salvage, infarct size, and microvascular damage in patients with ST-segment elevation myocardial infarction: insight from cardiovascular magnetic resonance","volume":"54","author":"Francone","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.pcad.2015.08.007_bb0015","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1161\/01.CIR.0000121424.76486.20","article-title":"Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts","volume":"109","author":"De Luca","year":"2004","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.pcad.2015.08.007_bb0020","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jacc.2012.07.008","article-title":"Reduction in mortality as a result of direct transport from the field to a receiving center for primary percutaneous coronary intervention","volume":"60","author":"Le May","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.pcad.2015.08.007_bb0025","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.pcad.2015.08.007_bb0030","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.pcad.2015.08.007_bb0035","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jacc.2012.06.017","article-title":"Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study","volume":"60","author":"Romagnoli","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.pcad.2015.08.007_bb0040","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"issue":"37","key":"10.1016\/j.pcad.2015.08.007_bb0045","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Authors\/Task Force, m","year":"2014","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.pcad.2015.08.007_bb0050","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jcin.2011.02.011","volume":"4","author":"Mehran","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"10.1016\/j.pcad.2015.08.007_bb0055","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1161\/CIRCINTERVENTIONS.109.928721","article-title":"Incidence, predictors, and prognostic implications of hospitalization for late bleeding after percutaneous coronary intervention for patients older than 65years","volume":"3","author":"Ko","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"issue":"9","key":"10.1016\/j.pcad.2015.08.007_bb0060","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.amjcard.2005.06.056","article-title":"Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes","volume":"96","author":"Rao","year":"2005","journal-title":"Am J Cardiol"},{"issue":"24","key":"10.1016\/j.pcad.2015.08.007_bb0065","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1161\/01.CIR.103.24.2994","article-title":"Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association","volume":"103","author":"Hirsh","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2015.08.007_bb0070","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1152\/ajplegacy.1916.41.2.250","article-title":"The thromboplastic action of cephalin","volume":"41","author":"McLean","year":"1916","journal-title":"Am J Physiol"},{"issue":"8607","key":"10.1016\/j.pcad.2015.08.007_bb0075","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2","volume":"2","author":"ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","year":"1988","journal-title":"Lancet"},{"issue":"8796","key":"10.1016\/j.pcad.2015.08.007_bb0080","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0140-6736(92)91893-D","article-title":"ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction","volume":"339","author":"ISIS-3 (Third International Study of Infarct Survival) Collaborative Group","year":"1992","journal-title":"Lancet"},{"issue":"8707","key":"10.1016\/j.pcad.2015.08.007_bb0085","first-page":"65","article-title":"GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico","volume":"336","year":"1990","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.pcad.2015.08.007_bb0090","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","author":"The GUSTO investigators","year":"1993","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.pcad.2015.08.007_bb0095","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJM199311253292204","article-title":"The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction","volume":"329","author":"The GUSTO Angiographic Investigators","year":"1993","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pcad.2015.08.007_bb0100","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1055\/s-0038-1648515","article-title":"Heparin binding to plasma proteins, an important mechanism for heparin resistance","volume":"67","author":"Young","year":"1992","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.pcad.2015.08.007_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-9560-11-7","article-title":"Emphasis on the role of PF4 in the incidence, pathophysiology and treatment of heparin induced thrombocytopenia","volume":"11","author":"Prechel","year":"2013","journal-title":"Thromb J"},{"issue":"18","key":"10.1016\/j.pcad.2015.08.007_bb0110","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1182\/blood-2010-09-307751","article-title":"Heparin promotes platelet responsiveness by potentiating alphaIIbbeta3-mediated outside-in signaling","volume":"117","author":"Gao","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pcad.2015.08.007_bb0115","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s11886-008-0050-0","article-title":"Which heparin and how much?","volume":"10","author":"Ruchin","year":"2008","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"10.1016\/j.pcad.2015.08.007_bb0120","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ccd.21062","article-title":"A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study","volume":"70","author":"Welsh","year":"2007","journal-title":"Catheter Cardiovasc Interv"},{"issue":"14","key":"10.1016\/j.pcad.2015.08.007_bb0125","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1161\/01.CIR.0000013402.34759.46","article-title":"Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial","volume":"105","author":"Antman","year":"2002","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.pcad.2015.08.007_bb0130","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1161\/CIRCULATIONAHA.105.595397","article-title":"Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial","volume":"112","author":"Sabatine","year":"2005","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.pcad.2015.08.007_bb0135","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1503\/cmaj.051410","article-title":"Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data","volume":"174","author":"Armstrong","year":"2006","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.pcad.2015.08.007_bb0140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.0000081659.72985.A8","volume":"108","author":"Wallentin","year":"2003","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.pcad.2015.08.007_bb0145","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa060898","article-title":"Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction","volume":"354","author":"Antman","year":"2006","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.pcad.2015.08.007_bb0150","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/eurheartj\/ehm224","article-title":"Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis","volume":"28","author":"Murphy","year":"2007","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.pcad.2015.08.007_bb0155","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ahj.2011.10.015","article-title":"Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction: insights from the TRANSFER-AMI trial","volume":"163","author":"Lavi","year":"2012","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.pcad.2015.08.007_bb0160","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ahj.2005.04.005","volume":"150","author":"Investigators","year":"2005","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.pcad.2015.08.007_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2003.07.025","article-title":"Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial","volume":"147","author":"Ellis","year":"2004","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.pcad.2015.08.007_bb0170","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jcin.2009.11.012","article-title":"Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)","volume":"3","author":"Montalescot","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"issue":"9792","key":"10.1016\/j.pcad.2015.08.007_bb0175","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(11)60876-3","article-title":"Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial","volume":"378","author":"Montalescot","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.pcad.2015.08.007_bb0180","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.amjcard.2013.07.003","article-title":"A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial)","volume":"112","author":"Collet","year":"2013","journal-title":"Am J Cardiol"},{"issue":"6-7","key":"10.1016\/j.pcad.2015.08.007_bb0185","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.acvd.2012.04.002","article-title":"Comparison of bleeding complications and 3-year survival with low-molecular-weight heparin versus unfractionated heparin for acute myocardial infarction: the FAST-MI registry","volume":"105","author":"Puymirat","year":"2012","journal-title":"Arch Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.pcad.2015.08.007_bb0190","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1160\/TH07-07-0449","article-title":"Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction","volume":"99","author":"Zeymer","year":"2008","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.pcad.2015.08.007_bb0195","doi-asserted-by":"crossref","first-page":"524","DOI":"10.4244\/EIJV4I4A88","article-title":"Efficacy and safety of enoxaparin in combination with and without GP IIb\/IIIa inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention","volume":"4","author":"Zeymer","year":"2009","journal-title":"EuroIntervention"},{"issue":"2","key":"10.1016\/j.pcad.2015.08.007_bb0200","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ccd.22674","article-title":"Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention","volume":"77","author":"Brieger","year":"2011","journal-title":"Catheter Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.pcad.2015.08.007_bb0205","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/01.CIR.0000136830.65073.C7","article-title":"Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin","volume":"110","author":"Montalescot","year":"2004","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.pcad.2015.08.007_bb0210","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.pcad.2015.08.007_bb0215","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/01.CIR.100.4.437","article-title":"Platelet glycoprotein IIb\/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?","volume":"100","author":"Scarborough","year":"1999","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.pcad.2015.08.007_bb0220","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1161\/01.CIR.0000019581.22812.B2","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors: recognition of a two-edged sword?","volume":"106","author":"Quinn","year":"2002","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.pcad.2015.08.007_bb0225","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jacc.2004.06.050","article-title":"Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction","volume":"44","author":"Ernst","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.pcad.2015.08.007_bb0230","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1016\/j.jacc.2009.11.091","article-title":"Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome","volume":"55","author":"ten Berg","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.pcad.2015.08.007_bb0235","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1161\/CIRCINTERVENTIONS.108.847582.108.847582","volume":"2","author":"Le May","year":"2009","journal-title":"Circ Cardiovasc Interv"},{"issue":"14","key":"10.1016\/j.pcad.2015.08.007_bb0240","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.108.818617","article-title":"Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial","volume":"119","author":"Mehilli","year":"2009","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.pcad.2015.08.007_bb0245","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jcin.2011.11.009","article-title":"Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study","volume":"5","author":"Wijnbergen","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"issue":"11","key":"10.1016\/j.pcad.2015.08.007_bb0250","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/heartjnl-2013-305374","article-title":"Rise and fall of glycoprotein IIb-IIIa inhibitors in ST-segment elevation myocardial infarction","volume":"100","author":"Di Mario","year":"2014","journal-title":"Heart"},{"issue":"9957","key":"10.1016\/j.pcad.2015.08.007_bb0255","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial","volume":"384","author":"Shahzad","year":"2014","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.pcad.2015.08.007_bb0260","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jama.2015.2323","article-title":"Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial","volume":"313","author":"Han","year":"2015","journal-title":"JAMA"},{"issue":"4 Suppl. S","key":"10.1016\/j.pcad.2015.08.007_bb0265","doi-asserted-by":"crossref","first-page":"70S","DOI":"10.1016\/S0735-1097(02)02687-6","article-title":"The evolving role of direct thrombin inhibitors in acute coronary syndromes","volume":"41","author":"Eikelboom","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.pcad.2015.08.007_bb0270","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.pcad.2015.08.007_bb0275","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pcad.2015.08.007_bb0280","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1161\/CIRCINTERVENTIONS.112.968966","article-title":"Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry","volume":"5","author":"Hibbert","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"issue":"21","key":"10.1016\/j.pcad.2015.08.007_bb0285","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"issue":"9696","key":"10.1016\/j.pcad.2015.08.007_bb0290","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(09)61484-7","article-title":"Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial","volume":"374","author":"Mehran","year":"2009","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.pcad.2015.08.007_bb0295","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"Steg","year":"2013","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.pcad.2015.08.007_bb0300","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1093\/eurheartj\/ehu214","article-title":"Bivalirudin is superior to heparins alone with bailout GP IIb\/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial","volume":"35","author":"Zeymer","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.pcad.2015.08.007_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-9560-1-1","article-title":"Point-of-care testing of hemostasis in cardiac surgery","volume":"1","author":"Prisco","year":"2003","journal-title":"Thromb J"},{"issue":"4","key":"10.1016\/j.pcad.2015.08.007_bb0315","doi-asserted-by":"crossref","first-page":"E266","DOI":"10.1002\/ccd.23390","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"82","author":"Levine","year":"2013","journal-title":"Catheter Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.pcad.2015.08.007_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/CIRCINTERVENTIONS.115.002576","article-title":"Activated clotting time during percutaneous coronary intervention: a test for all seasons or a mind tranquilizer?","volume":"8","author":"Ndrepepa","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2015.08.007_bb0325","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jama.2015.2323","article-title":"Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial","volume":"313","author":"Han","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2015.08.007_bb0330","series-title":"American College of Cardiology\/i2 Scientific Session; March 16, 2015; San Diego, CA","author":"Valgimigli","year":"2015"},{"issue":"9943","key":"10.1016\/j.pcad.2015.08.007_bb0335","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(14)61216-2","article-title":"Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials","volume":"384","author":"Cavender","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2015.08.007_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.g6419","article-title":"Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors","volume":"349","author":"Bangalore","year":"2014","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.pcad.2015.08.007_bb0345","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/016327870202500206","article-title":"Individualizing treatment decisions. The likelihood of being helped or harmed","volume":"25","author":"Straus","year":"2002","journal-title":"Eval Health Prof"},{"issue":"11","key":"10.1016\/j.pcad.2015.08.007_bb0350","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jcin.2012.07.012","article-title":"Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes","volume":"5","author":"Dangas","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"issue":"23","key":"10.1016\/j.pcad.2015.08.007_bb0355","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A risk score to predict bleeding in patients with acute coronary syndromes","volume":"55","author":"Mehran","year":"2010","journal-title":"J Am Coll Cardiol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062015000663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062015000663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T12:43:56Z","timestamp":1718023436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062015000663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0033062015000663"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2015.08.007","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Ideal Anticoagulation Strategy in ST-Elevation Myocardial Infarction","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2015.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}